当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice.

Quantification of 4-hydroxyifosfamide in plasma of ifosfamide-treated mice.

Abstract：

PURPOSE:Ifosfamide is becoming an important clinical anticancer drug. Meaningful pharmacology studies require quantification of its activated and active metabolites, 4-hydroxyifosfamide (HOIfos) and isophosphoramide mustard (IPM), respectively. METHODS:Current methodology for quantifying the unstable HOIfos in biological fluids consists of trapping acrolein as it is produced during the decomposition of this metabolite. However, unlike cyclophosphamide, ifosfamide is extensively metabolized to two dechloroethylated metabolites, which are susceptible to 4-hydroxylation and similarly are capable of yielding acrolein upon decomposition. Because the current method has the potential to yield higher than actual values for HOIfos, it was compared with an HOIfos-specific method that traps the first stage degradation product of HOIfos, aldoifosfamide, as its semicarbazone, and depends on the use of radiolabeled drug for quantification. Six experiments in mice were conducted with blood collection 15 or 30 min after drug treatment followed by determination of HOIfos in plasma by the two methods. RESULTS:Comparison of plasma levels of HOIfos determined by the two methods indicated only minor differences between the two. CONCLUSION:These results suggest the possibility that the nonspecific method may be acceptable as a first estimation of levels of this metabolite in biological fluids until the development of a specific method that does not require radiolabeled drug, such as high-performance liquid chromatography or gas chromatography/mass spectrometry, has been developed.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Struck RF,McCain DM,Tendian SW,Tillery KH

doi

10.1007/s002800050625

subject

Has Abstract

pub_date

1997-01-01 00:00:00

pages

57-9

issue

1

eissn

0344-5704

issn

1432-0843

journal_volume

40

pub_type

杂志文章

相关文献

CANCER CHEMOTHERAPY AND PHARMACOLOGY文献大全
  • Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.

    abstract：:Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mea...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00434388

    authors： Howell SB,Mansfield SJ,Taetle R

    更新日期：1981-01-01 00:00:00

  • Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.

    abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050744

    authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

    更新日期：1998-01-01 00:00:00

  • A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.

    abstract：INTRODUCTION:Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. MATERIAL AND METHODS:A retrospective review of 183 patients submitted to second-line thera...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-007-0653-y

    authors： Reni M,Berardi R,Mambrini A,Pasetto L,Cereda S,Ferrari VD,Cascinu S,Cantore M,Mazza E,Grisanti S

    更新日期：2008-09-01 00:00:00

  • Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species.

    abstract：:Saturable elimination of 5-FU is exhibited in rats during constant infusions. Over the range of 3-480 mg/m2/h, total-body clearance of 5-FU decreases from 600 ml/min/m2 to less than 90 ml/min/m2. Previously published values for catabolism of 5-FU by rat hepatocytes can be used to simulate the plasma concentrations of ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00434346

    authors： Collins JM

    更新日期：1985-01-01 00:00:00

  • A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.

    abstract：BACKGROUND:Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to establish the maximu...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-020-04224-8

    authors： Thomas JS,El-Khoueiry AB,Maurer BJ,Groshen S,Pinski JK,Cobos E,Gandara DR,Lenz HJ,Kang MH,Reynolds CP,Newman EM

    更新日期：2021-01-10 00:00:00

  • Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.

    abstract：PURPOSE:To investigate the safety of intravenous topotecan monotherapy for relapsed small cell lung cancer (SCLC) patients with pre-existing interstitial lung disease (ILD). METHODS:A total of 77 patients who received topotecan for the treatment of relapsed SCLC between April 2007 and April 2014 were reviewed. Patient...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2816-6

    authors： Enomoto Y,Inui N,Imokawa S,Karayama M,Hasegawa H,Ozawa Y,Matsui T,Yokomura K,Suda T

    更新日期：2015-09-01 00:00:00

  • Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

    abstract：PURPOSE:Curcumin, a major constituent of the spice turmeric, suppresses expression of the enzyme cyclooxygenase 2 (Cox-2) and has cancer chemopreventive properties in rodents. It possesses poor systemic availability. We explored whether formulation with phosphatidylcholine increases the oral bioavailability or affects ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-006-0355-x

    authors： Marczylo TH,Verschoyle RD,Cooke DN,Morazzoni P,Steward WP,Gescher AJ

    更新日期：2007-07-01 00:00:00

  • Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.

    abstract：PURPOSE:Oxaliplatin (OHP) in combination with 5-fluorouracil/leucovorin (FOLFOX) is clinically used as frontline therapy in patients with advanced colorectal carcinoma (CRC), with response rates ranging from 46 to 71%. This combination is now considered a standard treatment for metastatic CRC and also in the post-opera...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-010-1476-9

    authors： Garg MB,Ackland SP

    更新日期：2011-04-01 00:00:00

  • Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

    abstract：:cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients. Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2. Following this, doses were given every 4 weeks and escalated from 300...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00257742

    authors： Calvert AH,Harland SJ,Newell DR,Siddik ZH,Jones AC,McElwain TJ,Raju S,Wiltshaw E,Smith IE,Baker JM,Peckham MJ,Harrap KR

    更新日期：1982-01-01 00:00:00

  • Timed sequential chemotherapy following ifosfamide-induced kinetic recruitment in refractory ovarian cancer.

    abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685417

    authors： Rosso R,Alama A,Repetto L,Conte PF

    更新日期：1990-01-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.

    abstract：PURPOSE:The plasma and cerebrospinal fluid (CSF) pharmacokinetics of the camptothecin analogs, 9-aminocamptothecin (9-AC) and irinotecan, were studied in a nonhuman primate model to determine their CSF penetration. METHODS:9-AC, 0.2 mg/kg (4 mg/m2) or 0.5 mg/kg (10 mg/m2), was infused intravenously over 15 min and iri...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050768

    authors： Blaney SM,Takimoto C,Murry DJ,Kuttesch N,McCully C,Cole DE,Godwin K,Balis FM

    更新日期：1998-01-01 00:00:00

  • Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.

    abstract：:Tumor angiogenesis is essential for tumor growth and metastasis formation. Luminex methodology was used to measure the levels of four angiogenic cytokines in cell culture medium and in the plasma of mice bearing human tumors. We obtained plasma and conditioned culture medium from 12 different human tumor cell lines. T...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0572-5

    authors： Keyes KA,Mann L,Cox K,Treadway P,Iversen P,Chen YF,Teicher BA

    更新日期：2003-04-01 00:00:00

  • Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

    abstract：:Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent wit...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00253006

    authors： Israel M,Karkowsky AM,Khetarpal VK

    更新日期：1981-01-01 00:00:00

  • A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer.

    abstract：:Carboplatin is an alternative for cisplatin in the treatment of urothelial cancers. A pharmacologically guided phase I study of carboplatin in combination with methotrexate (30 mg/m2) and vinblastine (4 mg/m2) was conducted in ten patients by increment of the area under the plasma concentration versus time curve (AUC)...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050252

    authors： Chatelut E,Chevreau C,Brunner V,Martinez M,Houin G,Bugat R,Canal P

    更新日期：1995-01-01 00:00:00

  • Histone deacetylases and transcriptional therapy with their inhibitors.

    abstract：:Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hemopoietic development and is invariably associated with reciprocal chromosomal translocations involving the retinoic acid receptor alpha (RARalpha) gene on chromosome 17. RARalpha var...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,评审

    doi：10.1007/s002800100322

    authors： Pandolfi PP

    更新日期：2001-08-01 00:00:00

  • Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein.

    abstract：PURPOSE:The intra-tumour distribution of anticancer drugs remains an important, but often under-estimated, influence on drug efficacy. Tumour acidity and the presence of efflux pumps were examined for their influence on the distribution of doxorubicin in a solid tumour model. METHODS:Anticancer drug distribution and o...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-011-1598-8

    authors： Mellor HR,Callaghan R

    更新日期：2011-11-01 00:00:00

  • Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.

    abstract：UNLABELLED:A hemopoietin with the ability to accelerate both platelet and granulocyte recovery after intensive chemotherapy would have great clinical utility. The recombinant fusion protein composed of human granulocyte-macrophage colony-stimulating factor and interleukin-3 (PIXY321), showed some promise in early adult...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 临床试验,杂志文章

    doi：10.1007/s002800050733

    authors： Furman WL,Rodman JH,Tonda ME,Luo X,Arnold B,Marina N,Garrison L,Hanna R,Pratt CB,Meyer WH

    更新日期：1998-01-01 00:00:00

  • Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells.

    abstract：:Imidazoacridinones are a new class of highly potent antineoplastic agents synthesised at the Technical University of Gdansk. The pharmacophoric alkyldiamine group, which is also present in anthracenediones (e.g. ametantrone, mitoxantrone), has been shown to be responsible for their antineoplastic activity. In view of ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050445

    authors： Augustin E,Wheatley DN,Lamb J,Konopa J

    更新日期：1996-01-01 00:00:00

  • A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

    abstract：PURPOSE:To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. METHODS:Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s00280-009-1059-9

    authors： Oh DY,Cha Y,Choi IS,Yoon SY,Choi IK,Kim JH,Oh SC,Kim CD,Kim JS,Bang YJ,Kim YH

    更新日期：2010-02-01 00:00:00

  • Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.

    abstract：PURPOSE:S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS:The treatment consisted of four cycles of induction GS (S-1 ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-017-3350-5

    authors： Sudo K,Hara R,Nakamura K,Kita E,Tsujimoto A,Yamaguchi T

    更新日期：2017-07-01 00:00:00

  • The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium.

    abstract：PURPOSE:We reported the first case of phenytoin intoxication due to the concomitant use of phenytoin and TS-1, together with a review of the literature regarding the occurrence of phenytoin intoxication due to the concomitant use of phenytoin and fluoropyrimidine antitumor drugs such as fluorouracil (5-FU) and tegafur ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-007-0621-6

    authors： Tsuda A,Fujiyama J,Miki A,Hori S,Ohtani H,Sawada Y

    更新日期：2008-08-01 00:00:00

  • In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

    abstract：:The in vitro effect of the dextroisomer r-verapamil on blast cells derived from patients with acute myelogenous leukemia (AML) was studied. R-verapamil caused a dose-dependent inhibition of AML blast proliferation in the presence of stem-cell factor, leukemia inhibitory factor, interleukin 4, interleukin 6, and interl...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00685631

    authors： Bruserud O,Nesthus I,Pawelec G

    更新日期：1995-01-01 00:00:00

  • Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

    abstract：PURPOSE:RSR13, 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid monosodium salt, allosterically modifies hemoglobin to increase tumor pO(2), increases the effect of radiation in animal tumor models, and is in phase III clinical trials as an adjuvant to radiotherapy. Cisplatin and carboplat...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0715-8

    authors： Donnelly ET,Kelley M,Rockwell S

    更新日期：2004-01-01 00:00:00

  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

    abstract：:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was c...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/BF00435840

    authors： Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO

    更新日期：1989-01-01 00:00:00

  • Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.

    abstract：:Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-003-0706-9

    authors： Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

    更新日期：2004-01-01 00:00:00

  • Comparative brain tissue distribution of camptothecin and topotecan in the rat.

    abstract：PURPOSE:The primary objective of this investigation was to compare the extent of brain distribution of the lactone and the carboxylate forms of camptothecin (CPT) and topotecan (TPT) in awake freely moving rats. METHODS:The plasma concentration-time profiles of the lactone and the carboxylate forms of CPT and TPT were...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s002800050908

    authors： El-Gizawy SA,Hedaya MA

    更新日期：1999-01-01 00:00:00

  • Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.

    abstract：PURPOSE:This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients. METHODS:Five dose level combinations with irinotecan (from 180 to 240 mg/m(2), day 1, q21), capecitabine (1,...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-008-0852-1

    authors： Bajetta E,Di Bartolomeo M,Buzzoni R,Ferrario E,Dotti KF,Mariani L,Bajetta R,Gevorgyan A,Venturino P,Galassi M

    更新日期：2009-06-01 00:00:00

  • Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

    abstract：PURPOSE:This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS:Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled pralatrexate, methot...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-009-0954-4

    authors： Izbicka E,Diaz A,Streeper R,Wick M,Campos D,Steffen R,Saunders M

    更新日期：2009-10-01 00:00:00

  • Population pharmacokinetics of bevacizumab in cancer patients with external validation.

    abstract：BACKGROUND:Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS:Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early a...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-016-3079-6

    authors： Han K,Peyret T,Marchand M,Quartino A,Gosselin NH,Girish S,Allison DE,Jin J

    更新日期：2016-08-01 00:00:00

  • Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.

    abstract：PURPOSE:It remains challenging to identify patients at risk of anthracycline-induced cardiotoxicity. To better understand the different risk-stratifying approaches, we evaluated (123)I-metaiodobenzylguanidine ((123)I-mIBG) scintigraphy and its interrelationship with conventional echocardiography, 2D strain imaging and ...

    journal_title：Cancer chemotherapy and pharmacology

    pub_type： 杂志文章

    doi：10.1007/s00280-015-2874-9

    authors： Bulten BF,Verberne HJ,Bellersen L,Oyen WJ,Sabaté-Llobera A,Mavinkurve-Groothuis AM,Kapusta L,van Laarhoven HW,de Geus-Oei LF

    更新日期：2015-11-01 00:00:00